All In Biotech

Drug Trial Radar · NCT07089706

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

A Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine Formulations

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

832

Actual

Start

Jul 21, 2025

Primary completion

Jun 16, 2026

Study completion Jun 16, 2026

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.

Conditions

  • COVID-19

Interventions

  • mRNA-1283.251 Variant-containing FormulationBiological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subprotocol 1: Part A - Geometric Mean (GM) Value of Neutralizing Antibody (nAb) Against Vaccine-matched COVID-19 VariantsTime frame: Day 29
  2. Subprotocol 1: Part A - Geometric Mean Fold Rise (GMFR) of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29
  3. Subprotocol 1: Part B - GMFR of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29
  4. Subprotocol 1: Part A - Seroresponse Rate (SRR) of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • DelRicht Research-Atlanta

    Atlanta, Georgia

  • DelRicht Research-Baton Rouge

    Baton Rouge, Louisiana

  • DelRicht Research-New Orleans

    New Orleans, Louisiana

  • DelRicht Research-Gulfport

    Gulfport, Mississippi

  • DelRicht Research-Tulsa

    Tulsa, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.